GW enters cannabis drug alliance with Otsuka
The financial terms of this agreement include total milestone payments to GW of up to GBP273 million as well as commercial supply price and royalty. Otsuka will pay
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.